Planned
IPAX3 (131I-TLX-203)
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)
- Principal investigator : Prof. dr. Paul Clement
- Sponsor: Telix Pharma
- More information :
- Indication: Glioblastoma
- Internal reference number : s71171
MIRAGE-HN
A Phase II trial evaluating treatment intensification with ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor: Clinique universitaire Saint Luc
- More information :
- Indication:
- Internal reference number : s71428
OptimUM-11 - IDEA196-011
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF ADJUVANT DAROVASERTIB AND CRIZOTINIB IN PARTICIPANTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA
- Principal investigator : Prof. dr. Paul Clement
- Sponsor: IDEAYA
- More information :
- Indication:
- Internal reference number : s72531
Ongoing
MCLA-158-CL03
A phase III randomized, open label study to evaluate the efficacy and safety of Petosemtamab plus Pembrolizumab vs. Pembrolizumab in head and neck squamous cell carcinoma in the first line treatment of PD-L1+ (CPS≥1) metastatic/recurrent disease without curative therapy available.
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor: Merus
- More information : NCT06525220
- Indication:
- Internal reference number : s69060
Origami 5 (61186372HNC3001)
A Phase 3 Open-Label Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, In Comparison with Standard of Care Platinum/Pembrolizumab/5-FU, in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor: Johnson&Johnson
- More information :
- Indication:
- Internal reference number : s71117
VIGOR (EORTC 2427 BTG)
Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor: EORTC
- More information : NCT06809322
- Indication:
- Internal reference number : s70681